ClinicalTrials.gg
CompletedNCT04865770REMODELUpdated Feb 10, 2026Results posted

A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)

A Phase 3 interventional study of Semaglutide and Placebo (Semaglutide) in Diabetes Mellitus, Type 2 and Chronic Kidney Disease, sponsored by Novo Nordisk A/S. Completed at 49 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-10.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
106
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 163 studies testing semaglutide in Diabetes Mellitus, Type 2 — 35 open to participants now, 45 under way, 9 of them phase 3. Semaglutide · Diabetes Mellitus, Type 2.

Enrollment
80th of 163
106 · median 104
Started
2021
with 9 others
Phase 3
57 of 163
7 open now
Registered
85th of 163
by date
Lead sponsor
89 of 163
Novo Nordisk A/S

Among the 163 studies testing semaglutide in Diabetes Mellitus, Type 2, this one is the 80th largest by enrollment, is one of 10 that started in 2021, is one of 57 in phase 3, and was the 85th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

35 of the 163 studies testing semaglutide in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:

30 more — sign in →

By country, each count listing its studies:

All 35 open studies →

About semaglutide

Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 163 studies testing semaglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

We are doing this study to learn more about how semaglutide may help fight chronic kidney disease in people with type 2 diabetes. We are doing this by looking into how semaglutide works in the kidneys.

Participants will either get semaglutide or placebo (a 'dummy' medicine) - which treatment participants get is decided by chance.

Semaglutide is a medicine doctors can prescribe in some countries for the treatment of type 2 diabetes.

Participants will get the study medicine in a pen. Participants will use the pen to inject the medicine into the skin once a week.

The study will last for about 1 year. Participants will have 11 visits to the clinic, and 2 phone visits. Some of the visits could be in different locations.

Study staff will take blood samples at most of these visits. At 9 visits, participants will be asked to bring a sample of their first morning urine. At 4 of the visits participants will have to bring urine that they have collected over the last 24 hours.

The study includes magnetic resonance imaging (MRI) scans of participants' kidneys which is a test that shows a detailed picture of organs and other parts inside the body. The scan will last for 30 minutes, and is free of radiation.

03

Conditions studied

  • Diabetes Mellitus, Type 2
  • Chronic Kidney Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female.
  • Age above or equal to 18 years at the time of signing .
  • Diagnosed with T2D (type 2 diabetes) greater than or equal to 180 days prior to the day of screening.
  • (glycated haemoglobin) below or equal to 9.0 percent (below or equal to 75 mmol/mol).
  • Depending on /non-biopsy population:

    1. For subjects in the non-biopsy population: Serum creatinine-based greater than or equal to 30 and below or equal to 75 mL/min/1.73 m\^2(CKD-EPI).
    2. For subjects in the biopsy sub-population: Serum creatinine-based eGFR greater than or equal to 40 and below or equal to 75 mL/min/1.73 m\^2(CKD-EPI).
  • UACR ( Urinary albumin-to-creatinine ratio ) greater than or equal to 20 and below 5000 mg/g.
  • Treatment with maximum labelled or tolerated dose of a renin-angiotensin-aldosterone system (RAAS) blocking agent including an angiotensin converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB)) unless such treatment is or not tolerated.Treatment dose must be stable for at least 28 days prior to screening.

Exclusion criteria

Exclusion Criteria:

  • Use of any glucagon-like peptide 1 receptor agonist (GLP-1 RA) within 30 days prior to screening.
  • A prior solid organ transplant or awaiting solid organ transplant.
  • Myocardial infarction, stroke, hospitalisation for unstable angina pectoris or within 180 days prior to the day of screening.
  • Presence or history of malignant neoplasms (other than basal or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) within 5 years prior to the day of screening.
  • Congenital or hereditary kidney diseases including polycystic kidney disease, kidney diseases including glomerulonephritis or congenital urinary tract malformations.
  • Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within the past 90 days prior to screening or in the period between screening and Visit 2. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
  • Treatment with systemic anti-inflammatory or drugs within 90 days prior to screening. Stable treatment with acetylsalicylic acid for prevention of cardiovascular events and occasional use of propionic acid derivatives drugs (e.g. ibuprofen) is allowed.
  • Any for MRI according to standard checklist used in clinical routine, including claustrophobia or metallic foreign bodies, metallic implants, internal electrical devices, or permanent makeup/tattoos that cannot be declared MR compatible.
  • Combination use of an ACE (angiotensin-converting enzyme) inhibitor and an ARB (angiotensin II receptor blockers).
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
106 participants (actual)

Study arms

  • Experimental
    Semaglutide 1.0 mg OW

    Once-weekly (OW) Semaglutide administered subcutaneously (s.c., under the skin).

    Drug: Semaglutide

  • Placebo comparator
    Placebo (Semaglutide) 1.0 mg OW

    Once-weekly (OW) placebo (Semaglutide) administered subcutaneously (s.c., under the skin).

    Drug: Placebo (Semaglutide)

Interventions

  • Semaglutide given subcutaneously (sc, under the skin) once weekly. Dose gradually increased over 8 weeks from 0.25 to 1.0 mg. The study will last for about 1 year.

  • DrugPlacebo (Semaglutide)

    Placebo (Semaglutide) given subcutaneously (sc, under the skin) once weekly. Dose gradually increased over 8 weeks from 0.25 to 1.0 mg. The study will last for about 1 year.

06

What researchers measure

Primary outcomes

  1. Change in Kidney Oxygenation (Cortex), Blood Oxygenation-level Dependent Magnetic Resonance Imaging (BOLD MRI) (R2*)

    Change in kidney oxygenation in cortex assessed by BOLD (blood oxygenation level dependent) MRI from baseline (week 0) to end of treatment (week 52) is presented. R2\* is a measure used in BOLD MRI to indicate the level of tissue oxygenation. A higher R2\* value means lower tissue oxygenation while a lower R2\* value means higher tissue oxygenation.

    Time frame: Baseline (week 0), End of treatment (week 52)

  2. Change in Kidney Oxygenation (Medulla), BOLD MRI (R2*)

    Change in kidney oxygenation in medulla assessed by BOLD (blood oxygenation level dependent) MRI from baseline (week 0) to end of treatment (week 52) is presented. R2\* is a measure used in BOLD MRI to indicate the level of tissue oxygenation. A higher R2\* value means lower tissue oxygenation while a lower R2\* value means higher tissue oxygenation.

    Time frame: Baseline (week 0), End of treatment (week 52)

  3. Change in Global Kidney Perfusion (MRI)

    Change in global kidney perfusion assessed by phase contrast MRI from baseline (week 0) to end of treatment (week 52) is presented.

    Time frame: Baseline (week 0), End of treatment (week 52)

  4. Change in Kidney Inflammation (Cortex), Longitudinal Relaxation Time (T1) Mapping (MRI)

    Change in kidney inflammation in cortex assessed by T1 mapping MRI from baseline (week 0) to end of treatment (week 52) is presented.

    Time frame: Baseline (week 0), End of treatment (week 52)

  5. Change in Kidney Inflammation (Medulla), T1 Mapping (MRI)

    Change in kidney inflammation in medulla assessed by T1 mapping MRI from baseline (week 0) to end of treatment (week 52) is presented.

    Time frame: Baseline (week 0), End of treatment (week 52)

Secondary outcomes

  1. Change in Gene Expression Assessed by Single Nucleus Ribonucleic Acid (RNA) Sequencing (Kidney Biopsy)

    Changes in gene expression were assessed by single nucleus RNA sequencing (kidney biopsies) from baseline (week 0) to end of treatment (week 52). Cell type annotation was performed prior to the analysis. The analysis reports the log2 fold change in form of differential gene expression per cell type from baseline, comparing treatment arms. Genes are considered significant if fold change \> 0.5 or \< 0.5 and false discovery rate (FDR) \<0.1; these criteria help identify biologically significant genes that are reliably differentially expressed in patients with conditions such as Type 2 diabetes and chronic kidney disease. The differential expression was estimated using a linear mixed model that included participant as a random effect. The cell types presented are those that contain these differentially expressed genes demonstrating the treatment response. This threshold is based on findings published in cross-sectional observational studies related to disease impact and gene activity.

    Time frame: Baseline (week 0), End of treatment (week 52)

  2. Change in Glomerular Basement Membrane Width (Kidney Biopsy)

    Change in glomerular basement membrane width assessed in kidney biopsy from baseline (week 0) to end of treatment (week 52) is presented.

    Time frame: Baseline (week 0), End of treatment (week 52)

  3. Change in Apparent Diffusion Coefficient (ADC) (Cortex) (MRI)

    Change in apparent diffusion coefficient in cortex assessed by MRI from baseline (week 0) to end of treatment (week 52) is presented.

    Time frame: Baseline (week 0), End of treatment (week 52)

  4. Change in Apparent Diffusion Coefficient (ADC) (Medulla) (MRI)

    Change in apparent diffusion coefficient in medulla assessed by MRI from baseline (week 0) to end of treatment (week 52) is presented.

    Time frame: Baseline (week 0), End of treatment (week 52)

  5. Change in Mean Renal Artery Resistive Index (RARI) (MRI)

    Change in renal arterial resistive index assessed by MRI from baseline (week 0) to end of treatment (week 52) is presented. RARI measures the preservation of blood flow in renal arteries throughout the cardiac cycle and is therefore a measure for resistance of blood flow within the renal arteries. It serves as an indicator of kidney vascular health and potential arterial stiffness or obstruction. It is prognostic for primary cardiovascular and renal events in type 2 diabetes, where a lower RARI predicts a lower rate of events. RARI is calculated by relating the difference between blood flow at maximum velocity during the cardiac contraction phase (peak systolic velocity, PSV) and the speed at the end of the relaxation phase, at the point of minimal velocity (end diastolic velocity, EDV) with PSV, i.e., RARI = (PSV-EDV)/PSV.

    Time frame: Baseline (week 0), End of treatment (week 52)

  6. Change in Mean Arterial Flow (MRI)

    Change in mean arterial flow assessed by MRI from baseline (week 0) to end of treatment (week 52) is presented.

    Time frame: Baseline (week 0), End of treatment (week 52)

  7. Change in Natriuresis (Urinary Sodium Excretion) (Urinalysis)

    Change in natriuresis (urinary sodium excretion) (urinalysis) from baseline (week 0) to end of treatment (week 52) is presented.

    Time frame: Baseline (week 0), End of treatment (week 52)

  8. Change in Albumin Excretion Rate (Urinalysis)

    Change in albumin excretion rate (urinalysis) from baseline (week 0) to end of treatment (week 52) is presented.

    Time frame: Baseline (week 0), End of treatment (week 52)

  9. Change in Kidney Function (Creatinine Clearance) (Urinalysis)

    Change in kidney function (creatinine clearance) (urinalysis) from baseline (week 0) to end of treatment (week 52) is presented.

    Time frame: Baseline (week 0), End of treatment (week 52)

07

Results

Posted Jan 14, 2026

Participant flow

The trial was conducted at 31 sites in 8 countries.

Participant flow — Overall Study
MilestoneSemaglutide 1.0 mgPlacebo
Started7135
Full analysis set7135
Safety analysis set7135
Completed5834
Not completed131
Withdrew: Withdrawal by subject30
Withdrew: Physician decision90
Withdrew: Death11

Outcome measures

PrimaryChange in Kidney Oxygenation (Cortex), Blood Oxygenation-level Dependent Magnetic Resonance Imaging (BOLD MRI) (R2*)

Change in kidney oxygenation in cortex assessed by BOLD (blood oxygenation level dependent) MRI from baseline (week 0) to end of treatment (week 52) is presented. R2\* is a measure used in BOLD MRI to indicate the level of tissue oxygenation. A higher R2\* value means lower tissue oxygenation while a lower R2\* value means higher tissue oxygenation.

Time frame:
Baseline (week 0), End of treatment (week 52)
Reported as:
Geometric mean · Ratio of kidney oxygenation (cortex)
Change in Kidney Oxygenation (Cortex), Blood Oxygenation-level Dependent Magnetic Resonance Imaging (BOLD MRI) (R2*)
Ratio of kidney oxygenation (cortex)Semaglutide 1.0 mgPlacebo
Bilateral cortex0.98 ± 5.351.00 ± 7.39
Right cortex0.98 ± 5.650.99 ± 7.26
Left cortex0.98 ± 7.511.01 ± 9.12
Statistical analysis
  • Semaglutide 1.0 mg vs Placebo · ANCOVA · p = 0.1333 · Treatment ratio: 0.98 · 95% CI 0.96 to 1.01
  • Semaglutide 1.0 mg vs Placebo · ANCOVA · p = 0.2487 · Treatment ratio: 0.99 · 95% CI 0.96 to 1.01
  • Semaglutide 1.0 mg vs Placebo · ANCOVA · p = 0.0907 · Treatment ratio: 0.97 · 95% CI 0.94 to 1.00
PrimaryChange in Kidney Oxygenation (Medulla), BOLD MRI (R2*)

Change in kidney oxygenation in medulla assessed by BOLD (blood oxygenation level dependent) MRI from baseline (week 0) to end of treatment (week 52) is presented. R2\* is a measure used in BOLD MRI to indicate the level of tissue oxygenation. A higher R2\* value means lower tissue oxygenation while a lower R2\* value means higher tissue oxygenation.

Time frame:
Baseline (week 0), End of treatment (week 52)
Reported as:
Geometric mean · Ratio of kidney oxygenation (medulla)
Change in Kidney Oxygenation (Medulla), BOLD MRI (R2*)
Ratio of kidney oxygenation (medulla)Semaglutide 1.0 mgPlacebo
Bilateral medulla0.99 ± 8.971.01 ± 11.37
Right medulla0.98 ± 10.091.02 ± 10.83
Left medulla0.99 ± 10.251.02 ± 13.02
Statistical analysis
  • Semaglutide 1.0 mg vs Placebo · ANCOVA · p = 0.5619 · Treatment ratio: 0.99 · 95% CI 0.94 to 1.03
  • Semaglutide 1.0 mg vs Placebo · ANCOVA · p = 0.2774 · Treatment ratio: 0.97 · 95% CI 0.93 to 1.02
  • Semaglutide 1.0 mg vs Placebo · ANCOVA · p = 0.7924 · Treatment ratio: 0.99 · 95% CI 0.94 to 1.04
PrimaryChange in Global Kidney Perfusion (MRI)

Change in global kidney perfusion assessed by phase contrast MRI from baseline (week 0) to end of treatment (week 52) is presented.

Time frame:
Baseline (week 0), End of treatment (week 52)
Reported as:
Geometric mean · Ratio of global kidney perfusion
Change in Global Kidney Perfusion (MRI)
Ratio of global kidney perfusionSemaglutide 1.0 mgPlacebo
Bilateral kidney1.03 ± 26.430.99 ± 24.39
Right kidney1.04 ± 27.840.98 ± 28.85
Left kidney1.02 ± 29.251.01 ± 26.83
Statistical analysis
  • Semaglutide 1.0 mg vs Placebo · ANCOVA · p = 0.0958 · Treatment ratio: 1.10 · 95% CI 0.98 to 1.24
  • Semaglutide 1.0 mg vs Placebo · ANCOVA · p = 0.0145 · Treatment ratio: 1.17 · 95% CI 1.03 to 1.33
  • Semaglutide 1.0 mg vs Placebo · ANCOVA · p = 0.3311 · Treatment ratio: 1.06 · 95% CI 0.94 to 1.21
PrimaryChange in Kidney Inflammation (Cortex), Longitudinal Relaxation Time (T1) Mapping (MRI)

Change in kidney inflammation in cortex assessed by T1 mapping MRI from baseline (week 0) to end of treatment (week 52) is presented.

Time frame:
Baseline (week 0), End of treatment (week 52)
Reported as:
Geometric mean · Ratio of kidney inflammation (cortex)
Change in Kidney Inflammation (Cortex), Longitudinal Relaxation Time (T1) Mapping (MRI)
Ratio of kidney inflammation (cortex)Semaglutide 1.0 mgPlacebo
Bilateral cortex1.01 ± 3.781.01 ± 5.43
Right cortex1.01 ± 3.881.01 ± 5.57
Left cortex1.01 ± 3.931.01 ± 5.71
Statistical analysis
  • Semaglutide 1.0 mg vs Placebo · ANCOVA · p = 0.8651 · Treatment ratio: 1.00 · 95% CI 0.98 to 1.02
  • Semaglutide 1.0 mg vs Placebo · ANCOVA · p = 0.7240 · Treatment ratio: 1.00 · 95% CI 0.98 to 1.02
  • Semaglutide 1.0 mg vs Placebo · ANCOVA · p = 0.7195 · Treatment ratio: 1.00 · 95% CI 0.98 to 1.02
PrimaryChange in Kidney Inflammation (Medulla), T1 Mapping (MRI)

Change in kidney inflammation in medulla assessed by T1 mapping MRI from baseline (week 0) to end of treatment (week 52) is presented.

Time frame:
Baseline (week 0), End of treatment (week 52)
Reported as:
Geometric mean · Ratio of kidney inflammation (medulla)
Change in Kidney Inflammation (Medulla), T1 Mapping (MRI)
Ratio of kidney inflammation (medulla)Semaglutide 1.0 mgPlacebo
Bilateral medulla1.00 ± 3.561.00 ± 5.13
Right medulla1.00 ± 3.901.01 ± 4.85
Left medulla1.00 ± 3.691.00 ± 5.91
Statistical analysis
  • Semaglutide 1.0 mg vs Placebo · ANCOVA · p = 0.9335 · Treatment ratio: 1.00 · 95% CI 0.98 to 1.02
  • Semaglutide 1.0 mg vs Placebo · ANCOVA · p = 0.6517 · Treatment ratio: 1.00 · 95% CI 0.98 to 1.01
  • Semaglutide 1.0 mg vs Placebo · ANCOVA · p = 0.9017 · Treatment ratio: 1.00 · 95% CI 0.98 to 1.02
SecondaryChange in Gene Expression Assessed by Single Nucleus Ribonucleic Acid (RNA) Sequencing (Kidney Biopsy)

Changes in gene expression were assessed by single nucleus RNA sequencing (kidney biopsies) from baseline (week 0) to end of treatment (week 52). Cell type annotation was performed prior to the analysis. The analysis reports the log2 fold change in form of differential gene expression per cell type from baseline, comparing treatment arms. Genes are considered significant if fold change \> 0.5 or \< 0.5 and false discovery rate (FDR) \<0.1; these criteria help identify biologically significant genes that are reliably differentially expressed in patients with conditions such as Type 2 diabetes and chronic kidney disease. The differential expression was estimated using a linear mixed model that included participant as a random effect. The cell types presented are those that contain these differentially expressed genes demonstrating the treatment response. This threshold is based on findings published in cross-sectional observational studies related to disease impact and gene activity.

Time frame:
Baseline (week 0), End of treatment (week 52)
Reported as:
Number · log2 fold-change
Change in Gene Expression Assessed by Single Nucleus Ribonucleic Acid (RNA) Sequencing (Kidney Biopsy)
log2 fold-changeSemaglutide 1.0 mg/Placebo
CNT-2, RSPO33.468216523
CNT-Immune, SLC8A1-AS12.8531071
EC-GC-1, KCNK6-1.952545192
EC-GC-1, EMC10-2.485824696
EC-GC-1, ENSG000002861451.831300888
EC-GC-1, LMF1-1.528463786
EC-GC-1, ANKUB11.783402404
EC-GC-1, AHNAK-1.368952211
EC-GC-1, ENSG000002861501.318309657
EC-GC-1, NSUN6-1.464540152
EC-GC-1, TFCP2L1-2.24516792
EC-GC-1, ENSG00000274422-1.860725608
EC-GC-1, DPYD-AS11.996950045
EC-GC-1, ENSG000002481382.110414741
EC-GC-1, ACSM2B-1.785467699
EC-GC-1, CCNH1.033873239
EC-GC-1, QTRT1-2.415240141
EC-GC-1, CROCCP3-1.254541813
EC-GC-1, ENSG000002510341.750285729
EC-GC-1, LSAMP-2.439268964
EC-GC-1, LHX1-DT-4.256689925
EC-GC-1, ESRRG-1.527414037
EC-GC-1, CNTNAP2-2.377391827
EC-GC-1, ENSG000002849661.665764749
EC-GC-1, BICC1-1.445239386
EC-GC-1, GNA14-AS11.192645521
EC-GC-1, GUSBP11-1.318511642
EC-GC-1, ENSG000002337831.668536087
EC-GC-1, SEMA6A-AS11.183886707
EC-GC-1, RBMS3-AS21.572052032
EC-GC-1, ENSG00000286147-4.468841041
EC-GC-1, LINC00342-1.151143461
EC-GC-1, IRF3-1.566408786
EC-GC-1, ENSG000002492071.35685803
EC-GC-1, CRADD-AS11.972404772
EC-GC-1, TOX3-2.206055055
EC-GC-1, ENSG000002864581.271036656
EC-GC-1, SLC12A3-2.531722898
EC-GC-1, TALAM11.235573321
EC-GC-1, PCDH171.107442597
EC-GC-1, ATP13A31.078246118
EC-GC-1, ENSG00000231772-2.382264501
EC-GC-1, FBXL19-2.166973377
EC-GC-1, ENSG000002544201.74612131
EC-GC-1, SPC251.329461228
EC-GC-1, SMAD41.13655744
EC-GC-1, UFM11.20264148
EC-GC-1, ENSG000002595642.071724947
EC-GC-1, SHOC11.634369451
EC-GC-1, MEF2C-AS21.753288691
EC-GC-1, ENSG000002858011.440844025
EC-GC-1, FAM228B-1.22996414
EC-GC-1, GLS0.868999317
EC-GC-1, GDPD4-6.564026305
EC-GC-1, INSYN2A1.759769032
EC-GC-1, TNFRSF14-1.254004029
EC-GC-1, PRX-1.199880651
EC-GC-1, PNN-1.024604708
EC-GC-1, KCNQ1OT1-0.794847103
EC-GC-1, ACAP3-1.44397269
EC-GC-1, BASP1-AS1-4.83539932
EC-GC-1, RBFOX1-1.706411849
EC-GC-1, CCDC90B-AS1-1.678217382
EC-GC-1, ENSG000002404991.514399208
EC-GC-1, LINC030761.545248095
EC-GC-1, LINC01409-1.022992954
EC-GC-1, CCT41.455396063
EC-GC-1, CDC730.802691458
EC-GC-1, NUMA1-0.931923316
EC-GC-1, FLT4-0.935590968
EC-GC-1, PDLIM50.764926487
EC-GC-1, SPCS31.02068757
EC-GC-1, ENSG000002506461.917331079
EC-GC-1, ENSG000002581681.083991656
EC-GC-1, ST8SIA40.901071433
EC-GC-1, BCL2L1-AS11.262413164
EC-GC-1, NRSN2-AS1-1.275348201
EC-GC-1, STARD13-AS1.148054491
EC-GC-1, CFLAR-AS11.168941896
EC-GC-1, PRKAR1A1.257792414
EC-GC-1, ENSG000002262391.126077043
EC-GC-1, CTNNA3-1.819759686
EC-GC-1, KCNK5-2.491597199
EC-GC-1, ESR21.071576206
EC-GC-1, SLC25A461.062235788
EC-GC-1, REV3L0.792446528
EC-GC-1, ZC2HC1C2.027909336
EC-GC-1, ENSG00000279686-1.453758633
EC-GC-1, ACER1-5.256214457
EC-GC-1, MALRD1-2.36001857
EC-GC-1, RRBP1-0.837125744
EC-GC-1, ZNF451-AS11.853753635
EC-GC-1, SHANK2-1.481833304
EC-GC-1, ENSG000002483882.196067138
EC-GC-1, KPNA50.936135624
EC-GC-1, APPAT-1.750949862
EC-GC-1, PCNT-0.932423432
EC-GC-1, ENSG000002338482.752498803
EC-GC-1, MORF4L21.28059543
EC-GC-1, ENSG00000236283-1.572597604
EC-GC-1, SNRNP70-0.883484114
EC-GC-1, EXD3-0.805539835
EC-GC-1, CNTNAP5-2.392758482
EC-GC-1, CASR-2.323412555
EC-GC-1, ENSG000002856921.124516569
EC-GC-1, WDR81-2.102548546
EC-GC-1, ZNF160-0.907890266
EC-GC-1, CA12-1.63720477
EC-GC-1, MAPK8IP3-0.998528168
EC-GC-1, ABTB3-2.945080572
EC-GC-1, CHORDC11.047593755
EC-GC-1, FREM1-1.948982139
EC-GC-1, FXYD6-AS12.22442108
EC-GC-1, SPACA6-1.045439073
EC-GC-1, AGBL1-2.851170905
EC-GC-2, NES-2.451444521
EC-GC-2, ADARB2-3.212266234
EC-GC-2, SERPINB92.315559798
EC-GC-2, ENSG00000274422-2.329265154
EC-GC-2, BTNL9-2.01168798
EC-GC-2, CPEB21.51543417
EC-GC-2, TBX2-2.604511077
EC-GC-2, ENSG000002905602.378813977
EC-GC-2, CFAP541.988387042
EC-GC-2, ABI3BP1.57362138
EC-GC-2, SPACA6-1.724379529
EC-GC-2, ADAMTSL2-2.009897896
EC-GC-2, LZTS1-2.659531511
EC-GC-2, ENSG000002857441.889210245
EC-GC-2, ENSG00000225689-1.414674941
EC-GC-2, LUZP2-4.384000321
EC-GC-2, NCKAP5-1.592351284
EC-GC-2, FAT1-1.855192898
NKC-NKT, AGBL4-2.145446805
NKC-NKT, TFEC1.989578132
NKC-NKT, ENSG00000254186-2.913048038
NKC-NKT, PDE10A-2.170777761
NKC-NKT, SHANK2-2.431773845
PEC, RGS6-3.331377896
PEC, AHNAK-1.645129407
PT-2, LRRC4C-2.167101922
PT-2, DSCAM-3.104786855
PT-2, RCN3-1.636040003
SecondaryChange in Glomerular Basement Membrane Width (Kidney Biopsy)

Change in glomerular basement membrane width assessed in kidney biopsy from baseline (week 0) to end of treatment (week 52) is presented.

Time frame:
Baseline (week 0), End of treatment (week 52)
Reported as:
Mean · Nanometer (nm)
Change in Glomerular Basement Membrane Width (Kidney Biopsy)
Nanometer (nm)Semaglutide 1.0 mgPlacebo
Change in Glomerular Basement Membrane Width (Kidney Biopsy)-72.67 ± 96.60-8.66 ± 206.35
SecondaryChange in Apparent Diffusion Coefficient (ADC) (Cortex) (MRI)

Change in apparent diffusion coefficient in cortex assessed by MRI from baseline (week 0) to end of treatment (week 52) is presented.

Time frame:
Baseline (week 0), End of treatment (week 52)
Reported as:
Geometric mean · Ratio of ADC (cortex)
Change in Apparent Diffusion Coefficient (ADC) (Cortex) (MRI)
Ratio of ADC (cortex)Semaglutide 1.0 mgPlacebo
Bilateral cortex1.00 ± 6.560.94 ± 11.40
Left cortex1.01 ± 8.500.96 ± 10.48
Right cortex0.98 ± 6.700.93 ± 12.12
SecondaryChange in Apparent Diffusion Coefficient (ADC) (Medulla) (MRI)

Change in apparent diffusion coefficient in medulla assessed by MRI from baseline (week 0) to end of treatment (week 52) is presented.

Time frame:
Baseline (week 0), End of treatment (week 52)
Reported as:
Geometric mean · Ratio of ADC (medulla)
Change in Apparent Diffusion Coefficient (ADC) (Medulla) (MRI)
Ratio of ADC (medulla)Semaglutide 1.0 mgPlacebo
Bilateral medulla0.98 ± 8.900.94 ± 13.51
Left medulla0.99 ± 9.510.95 ± 13.41
Right medulla0.98 ± 10.000.93 ± 13.94
SecondaryChange in Mean Renal Artery Resistive Index (RARI) (MRI)

Change in renal arterial resistive index assessed by MRI from baseline (week 0) to end of treatment (week 52) is presented. RARI measures the preservation of blood flow in renal arteries throughout the cardiac cycle and is therefore a measure for resistance of blood flow within the renal arteries. It serves as an indicator of kidney vascular health and potential arterial stiffness or obstruction. It is prognostic for primary cardiovascular and renal events in type 2 diabetes, where a lower RARI predicts a lower rate of events. RARI is calculated by relating the difference between blood flow at maximum velocity during the cardiac contraction phase (peak systolic velocity, PSV) and the speed at the end of the relaxation phase, at the point of minimal velocity (end diastolic velocity, EDV) with PSV, i.e., RARI = (PSV-EDV)/PSV.

Time frame:
Baseline (week 0), End of treatment (week 52)
Reported as:
Geometric mean · Ratio of RARI
Change in Mean Renal Artery Resistive Index (RARI) (MRI)
Ratio of RARISemaglutide 1.0 mgPlacebo
Bilateral renalartery0.97 ± 7.001.01 ± 6.13
Right renalartery0.98 ± 8.381.01 ± 8.62
Left renalartery0.97 ± 7.441.01 ± 6.43
SecondaryChange in Mean Arterial Flow (MRI)

Change in mean arterial flow assessed by MRI from baseline (week 0) to end of treatment (week 52) is presented.

Time frame:
Baseline (week 0), End of treatment (week 52)
Reported as:
Geometric mean · Ratio of mean arterial flow
Change in Mean Arterial Flow (MRI)
Ratio of mean arterial flowSemaglutide 1.0 mgPlacebo
Bilateral renalartery0.96 ± 24.960.96 ± 25.06
Right renalartery0.97 ± 30.210.95 ± 29.09
Left renalartery0.96 ± 25.060.98 ± 27.38
SecondaryChange in Natriuresis (Urinary Sodium Excretion) (Urinalysis)

Change in natriuresis (urinary sodium excretion) (urinalysis) from baseline (week 0) to end of treatment (week 52) is presented.

Time frame:
Baseline (week 0), End of treatment (week 52)
Reported as:
Mean · Millimoles per day (mmol/day)
Change in Natriuresis (Urinary Sodium Excretion) (Urinalysis)
Millimoles per day (mmol/day)Semaglutide 1.0 mgPlacebo
Change in Natriuresis (Urinary Sodium Excretion) (Urinalysis)-7.3 ± 71.3-26.9 ± 85.2
SecondaryChange in Albumin Excretion Rate (Urinalysis)

Change in albumin excretion rate (urinalysis) from baseline (week 0) to end of treatment (week 52) is presented.

Time frame:
Baseline (week 0), End of treatment (week 52)
Reported as:
Mean · Milligrams per day (mg/d)
Change in Albumin Excretion Rate (Urinalysis)
Milligrams per day (mg/d)Semaglutide 1.0 mgPlacebo
Change in Albumin Excretion Rate (Urinalysis)-81.9 ± 708.8-233.2 ± 964.8
SecondaryChange in Kidney Function (Creatinine Clearance) (Urinalysis)

Change in kidney function (creatinine clearance) (urinalysis) from baseline (week 0) to end of treatment (week 52) is presented.

Time frame:
Baseline (week 0), End of treatment (week 52)
Reported as:
Mean · Milliliter per minute
Change in Kidney Function (Creatinine Clearance) (Urinalysis)
Milliliter per minuteSemaglutide 1.0 mgPlacebo
Change in Kidney Function (Creatinine Clearance) (Urinalysis)3.8 ± 26.6-12.6 ± 34.2

Adverse events

Collected over Up to week 57. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Semaglutide 1.0 mg2/71 (2.8%)14/71 (19.7%)15/71 (21.1%)
Placebo1/35 (2.9%)5/35 (14.3%)11/35 (31.4%)
Most frequent serious events
Showing 10 of 24
Most frequent serious events
EventSemaglutide 1.0 mgPlacebo
Acute kidney injuryRenal and urinary disorders4/710/35
DeathGeneral disorders0/711/35
OsteoarthritisMusculoskeletal and connective tissue disorders0/711/35
Peripheral ischaemiaVascular disorders0/711/35
Skin ulcerSkin and subcutaneous tissue disorders0/711/35
Urinary retentionRenal and urinary disorders0/711/35
Abdominal pain upperGastrointestinal disorders1/710/35
AngerPsychiatric disorders1/710/35
Arteriosclerosis coronary arteryCardiac disorders1/710/35
Blood creatinine increasedInvestigations1/710/35
Most frequent other events
Most frequent other events
EventSemaglutide 1.0 mgPlacebo
DiarrhoeaGastrointestinal disorders4/714/35
Diabetic retinopathyEye disorders4/712/35
NasopharyngitisInfections and infestations0/712/35
NauseaGastrointestinal disorders4/712/35
Upper respiratory tract infectionInfections and infestations1/712/35
COVID-19Infections and infestations4/710/35
Decreased appetiteMetabolism and nutrition disorders4/710/35

Baseline characteristics

Full analysis set included all participants randomly assigned to trial treatment and who took at least 1 dose of trial product.

Age, Continuous
Age, Continuous(Years)Semaglutide 1.0 mgPlaceboTotal
Mean65.4 ± 9.265.1 ± 11.365.3 ± 9.9
Sex: Female, Male
Sex: Female, Male(Participants)Semaglutide 1.0 mgPlaceboTotal
Female16925
Male552681
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Semaglutide 1.0 mgPlaceboTotal
Hispanic or Latino538
Not Hispanic or Latino592887
Unknown or Not Reported7411
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Semaglutide 1.0 mgPlaceboTotal
American Indian Or Alaska Native202
Black Or African American5510
Not Reported6410
White432265
Other404
Asian11415
08

Study locations

49 sites
  • University of Arizona-CaTs
    Tucson, Arizona 85724, United States
  • Academic Medical Research Institute
    Los Angeles, California 90022, United States
  • Roderick A. Comunale II MD Inc.
    National City, California 91950, United States
  • N America Res Inst - San Dimas
    San Dimas, California 91773, United States
  • UC Anschutz Medical Campus
    Aurora, Colorado 80045, United States
  • Advent Health-Res Inst
    Orlando, Florida 32804, United States
  • Atlanta Diabetes Associates
    Atlanta, Georgia 30318, United States
  • Emory University Hsptl - Atlanta
    Atlanta, Georgia 30322, United States
  • Endeavor Health Glenbook Hosp
    Evanston, Illinois 60201, United States
  • North Suburban Nephrology LLC
    Gurnee, Illinois 60031, United States
  • University of Minnesota Health Clinical
    Minneapolis, Minnesota 55455, United States
  • Clinical Research Consultants, LLC
    Kansas City, Missouri 64111, United States
  • Cleveland Clinic_Cleveland
    Cleveland, Ohio 44195, United States
  • Prolato Clinical Research Cntr
    Houston, Texas 77054, United States
  • Sun Research Institute
    San Antonio, Texas 78215, United States
  • NE Clin Res of San Antonio
    San Antonio, Texas 78233, United States
  • University of Texas San Antonio
    San Antonio, Texas 78284, United States
  • Univ of Washington Med Ctr
    Seattle, Washington 98195, United States
  • Providence Medical Research Center
    Spokane, Washington 99204, United States
  • Medical College Of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • LMC ClinRsrh Inc.Brampton
    Brampton, Ontario L6S 0C6, Canada
  • UHN-Toronto General Hospital
    Toronto, Ontario M5G 2N2, Canada
  • Nefrologisk Klinik P 2132
    Copenhagen, 2100, Denmark
  • Rigshospitalet - Nefrologisk Klinik P 2132
    Copenhagen, 2100, Denmark
  • Steno Diabetes Center Copenhagen
    Herlev, 2730, Denmark
  • Centre Hospitalier Universitaire Amiens Picardie-Site Sud
    Amiens, 80054, France
  • Centre Hospitalier Universitaire de Rouen - Hopital de Bois Guillaume
    Bois-Guillaume, 76230, France
  • Centre Hospitalier Universitaire Grenoble Alpes-Site Nord Michallon-2
    Grenoble - Cédex 09, 38043, France
  • Les Hopitaux de Chartres-Hopital Louis Pasteur
    Le Coudray, 28630, France
  • Chu de Reims-Hopital Maison Blanche
    Reims, 51092, France
  • Centre Hospitalier Universitaire de Toulouse-Hopital Rangueil
    Toulouse, 31059, France
  • Istituto Scientifico San Raffaele
    Milan, MI 20132, Italy
  • Azienda Ospedaliera Papa Giovanni XXIII
    Bergamo, 24127, Italy
  • Azienda Ospedaliera di Padova Clin.Med.3
    Padova, 35128, Italy
  • Presidio Ospedaliero Cisanello
    Pisa, 56124, Italy
  • Azienda Ospedaliero - Universitaria Sant'Andrea
    Roma, 00189, Italy
  • In-Vivo Sp. z o.o.
    Bydgoszcz, 85-048, Poland
  • Centrum Medyczne "Diabetika"
    Radom, 26-600, Poland
  • Uniwersytecki Szpital Kliniczny Nr 2 PUM W Szczecinie
    Szczecin, 70-111, Poland
  • Miedzyleski Szpital Specjalistyczny, Oddzial Nefrologiczny
    Warsaw, 04-749, Poland
  • Prywatny Gabinet Janusz Gumprecht
    Zabrze, 41-800, Poland
  • Maxwell Centre
    Durban, KwaZulu-Natal 4001, South Africa
  • Precise Clinical Solutions (Pty) Ltd
    Durban, KwaZulu-Natal 4092, South Africa
  • Lenmed Shifa Private Hospital
    Durban, KwaZulu-Natal 4901, South Africa
  • Prof Rayner_Division of Nephrology
    Cape Town, Western Cape 7925, South Africa
  • Hospital Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital de Bellvitge
    L'Hospitalet de Llobregat, 08907, Spain
  • Hospital Clinico Universitario de Valencia
    Valencia, 46010, Spain
  • Hospital Clínico Universitario de Valencia
    Valencia, 46010, Spain
09

References and documents

Publications

  • Pruijm M, Belmar N, Bjornstad P, Cherney DZI, Das V, Gunnarsson T, Hodgin JB, Schytz PA, Tuttle KR, Kretzler M. REMODELing mechanistic trials for kidney disease: a multimodal, tissue-centered approach to understand the renal mechanism of action of semaglutide. Kidney Int. 2026 Jan;109(1):6-16. doi: 10.1016/j.kint.2025.10.005. Epub 2025 Nov 7. PubMed 41207620 ↗
  • Natale P, Green SC, Tunnicliffe DJ, Pellegrino G, Toyama T, Strippoli GF. Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes. Cochrane Database Syst Rev. 2025 Feb 18;2(2):CD015849. doi: 10.1002/14651858.CD015849.pub2. PubMed 39963952 ↗
  • Mendonca L, Moura H, Chaves PC, Neves JS, Ferreira JP. The Impact of Glucagon-Like Peptide-1 Receptor Agonists on Kidney Outcomes: A Meta-Analysis of Randomized Placebo-Controlled Trials. Clin J Am Soc Nephrol. 2025 Feb 1;20(2):159-168. doi: 10.2215/CJN.0000000584. Epub 2024 Oct 8. PubMed 39480988 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2021 to primary completion in Nov 2024, 42 months.

Results were first posted in Jan 2026, 1 year 1 month after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 42 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2021
First posted
Apr 29, 2021
StartActual
Apr 28, 2021
Primary completionActual
Nov 21, 2024
CompletionActual
Nov 21, 2024
Results first posted
Jan 14, 2026
Last update
Feb 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04865770
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Apr 29, 2021
Start date
Apr 28, 2021
Primary completion
Nov 21, 2024
Completion
Nov 21, 2024
Results posted
Jan 14, 2026
Last update
Feb 10, 2026

Study contacts

Clinical Transparency (Dept.2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion